DBV TECHNOLOGIES (EPA:DBV)

PRESS RELEASE

published on 05/16/2024 at 22:30, 1 year 10 months ago

DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024 avec toutes les résolutions adoptées. La société se concentre sur le traitement des allergies alimentaires et autres affections immunologiques non satisfaites

Résultats Assemblée Générale Mixte DBV Technologies Allergies Alimentaires Options De Traitement
PRESS RELEASE

published on 05/16/2024 at 22:30, 1 year 10 months ago

DBV Technologies Announces Results of its 2024 Combined General Meeting
DBV Technologies announces successful results of its 2024 Combined General Meeting where shareholders approved all proposed resolutions. The Company focuses on treatment options for food allergies

Resolutions Combined General Meeting DBV Technologies Food Allergies Treatment Options
BRIEF

published on 05/09/2024 at 22:35, 1 year 10 months ago

DBV Technologies annonce sa participation à deux conférences investisseurs en mai

DBV Technologies Allergies Alimentaires JMP Sciences De La Vie H.C. Wainwright BioConnect Webdiffusion Conférence
BRIEF

published on 05/09/2024 at 22:35, 1 year 10 months ago

DBV Technologies announces its participation in two investor conferences in May

DBV Technologies Food Allergy JMP Life Sciences HC Wainwright BioConnect Conference Webcast
PRESS RELEASE

published on 05/09/2024 at 22:30, 1 year 10 months ago

Participation de DBV Technologies aux conférences investisseurs en mai
DBV Technologies participera aux conférences investisseurs en mai pour présenter les options de traitement des allergies alimentaires et conditions immunologiques, notamment avec sa plateforme Viaskin. Détails des événements disponibles sur le site web

Traitement Conférences Investisseurs DBV Technologies Allergies Alimentaires Viaskin
PRESS RELEASE

published on 05/09/2024 at 22:30, 1 year 10 months ago

DBV Technologies to Participate in Upcoming Investor Conferences
DBV Technologies to participate in two upcoming investor conferences in May, presenting its clinical-stage biopharmaceutical developments. Learn more about their innovative treatment options

Investor Conferences Biopharmaceutical DBV Technologies Food Allergies Immunologic Conditions
BRIEF

published on 05/07/2024 at 22:35, 1 year 10 months ago

DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités

Résultats Financiers DBV Technologies Efficacité Viaskin Peanut Nomination Affaires Réglementaires Évolution Trésorerie Essai Clinique VITESSE
BRIEF

published on 05/07/2024 at 22:35, 1 year 10 months ago

DBV Technologies publishes its financial results for the first quarter of 2024 and provides an update on its activities

DBV Technologies Financial Results Effectiveness Viaskin Peanut Regulatory Affairs Appointment Cash Flow Evolution VITESSE Clinical Trial
PRESS RELEASE

published on 05/07/2024 at 22:30, 1 year 10 months ago

DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités
DBV Technologies publie ses résultats financiers du premier trimestre 2024, recrutement en bonne voie pour VITESSE, nomination de Robert Pietrusko comme Directeur des Affaires Règlementaires

Résultats Financiers Affaires Réglementaires DBV Technologies VITESSE Robert Pietrusko
PRESS RELEASE

published on 05/07/2024 at 22:30, 1 year 10 months ago

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
DBV Technologies reports Q1 2024 financial results and business update, with VITESSE enrollment progress, appointment of Chief Regulatory Officer, and $101.5 million cash balance

Financial Results Q1 2024 DBV Technologies VITESSE Enrollment Chief Regulatory Officer

Published on 03/20/2026 at 23:00, 1 day 10 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 1 day 11 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 1 day 12 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 1 day 19 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 1 day 20 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/20/2026 at 22:45, 1 day 10 hours ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 12 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 12 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 1 day 12 hours ago

BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 20:05, 1 day 13 hours ago

INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action

View all EQS

Published on 03/20/2026 at 19:00, 1 day 14 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 1 day 14 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 1 day 15 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 1 day 15 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Published on 03/20/2026 at 17:45, 1 day 15 hours ago

Cie du Bois Sauvage : Jaarverslag 2025

View all LES ECHOS COMFI WIRE

News